Featured Jobs
|
Distributions Processor - Qualified Retirement Plans Anchor 3(16) Fiduciary Solutions, LLC
|
|
Retirement Combo Plan Administrator Heritage Pension Advisors, Inc.
|
|
DWC ERISA Consultants LLC
|
|
July Business Services
|
|
The Pension Source
|
|
Nova 401(k) Associates
|
|
EPIC RPS
|
|
Defined Benefit Specialist II or III Nova 401(k) Associates
|
|
Merkley Retirement Consultants
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
Search the News Archive
|
2 Matching News Items |
| 1. |
Fierce Pharma
Aug. 27, 2024
"When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Now, Cigna’s Express Scripts is following suit in a move that could further chip away at Humira’s market share. Express Scripts, which is Cigna’s pharmacy benefit unit, is removing branded Humira from its largest commercial formularies come 2025 in favor of biosimilar options from Teva, Sandoz and Boehringer Ingelheim."
|
| 2. |
Fierce Pharma
Aug. 21, 2024
"As Biogen's relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive kickbacks scheme, a multi-employer health benefit plan claimed in a new lawsuit.... 'Had Biogen not bribed the PBMs, the PBMs would have given generic Tecfidera more favorable placement on their formularies to promote the use of generic Tecfidera over the higher-cost Tecfidera and Vumerity,' the plaintiff's lawyers explained in the complaint." [Local No. 1 Health Fund v. Biogen, Inc., No. 24-7387 (N.D. Ill. complaint filed Aug. 16, 2024)]
|
|
Syntax Enhancements for Standard Searches
|